Skip to main content

Epidemiology of Pain Among Patients with Solid Metastatic Cancer During the Last Year of Life.

Publication ,  Journal Article
Chaudhry, I; Shafiq, M; Teo, I; Ozdemir, S; Malhotra, C; COMPASS Study Team
Published in: J Pain Res
2022

BACKGROUND: Despite medical advancements, pain is a major source of suffering at the end of life for patients with a solid metastatic cancer. We aimed to assess the trajectory of pain prevalence, severity, interference, and inadequacy of analgesia during the last year of life. METHODS: We analysed data from the last year of life of 345 decedents from a prospective cohort study of 600 patients with a solid metastatic cancer in Singapore. Patients were surveyed every 3 months and their pain outcomes (prevalence, severity, and interference) and inadequacy of analgesia were analysed. We used mixed-effects regressions to assess the association of pain outcomes with patients' time from death, demographics, and planned or unplanned hospitalisations. RESULTS: Prevalence of pain was higher in the last 2 months (65%) compared to 11 to 12 months (41%) before death. Pain severity and interference scores (mean ± SD) were also higher in the last month (severity: 2.5±2.6; interference: 2.6±3.0) compared to 12 months before death (severity: 1.4±2.0; interference: 1.4±2.0). At any time during the last year of life, 38% of the patients were prescribed non-steroidal anti-inflammatory drugs, 11% were prescribed weak-opioids and 29% were prescribed strong opioids. These analgesics were prescribed through either oral, topical or injectable route. Pain outcomes were significantly worse (p-value<0.05) for younger patients, those with higher education, and more financial difficulties, while interference was higher after an unplanned hospitalisation in the last month. Females reported higher pain severity score during their last year of life compared to males. For patients reporting moderate to severe pain, inadequacy of analgesia was lower in the last 2 months (43%) compared to 11 to 12 months before death (83%). CONCLUSION: Findings highlight the need for greater attention in monitoring and treatment of pain even earlier in the disease trajectory, and increased attention to patients discharged from an unplanned hospitalisation.

Duke Scholars

Published In

J Pain Res

DOI

ISSN

1178-7090

Publication Date

2022

Volume

15

Start / End Page

2949 / 2956

Location

New Zealand

Related Subject Headings

  • 3214 Pharmacology and pharmaceutical sciences
  • 3209 Neurosciences
  • 3202 Clinical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Chaudhry, I., Shafiq, M., Teo, I., Ozdemir, S., Malhotra, C., & COMPASS Study Team. (2022). Epidemiology of Pain Among Patients with Solid Metastatic Cancer During the Last Year of Life. J Pain Res, 15, 2949–2956. https://doi.org/10.2147/JPR.S375874
Chaudhry, Isha, Mahham Shafiq, Irene Teo, Semra Ozdemir, Chetna Malhotra, and COMPASS Study Team. “Epidemiology of Pain Among Patients with Solid Metastatic Cancer During the Last Year of Life.J Pain Res 15 (2022): 2949–56. https://doi.org/10.2147/JPR.S375874.
Chaudhry I, Shafiq M, Teo I, Ozdemir S, Malhotra C, COMPASS Study Team. Epidemiology of Pain Among Patients with Solid Metastatic Cancer During the Last Year of Life. J Pain Res. 2022;15:2949–56.
Chaudhry, Isha, et al. “Epidemiology of Pain Among Patients with Solid Metastatic Cancer During the Last Year of Life.J Pain Res, vol. 15, 2022, pp. 2949–56. Pubmed, doi:10.2147/JPR.S375874.
Chaudhry I, Shafiq M, Teo I, Ozdemir S, Malhotra C, COMPASS Study Team. Epidemiology of Pain Among Patients with Solid Metastatic Cancer During the Last Year of Life. J Pain Res. 2022;15:2949–2956.

Published In

J Pain Res

DOI

ISSN

1178-7090

Publication Date

2022

Volume

15

Start / End Page

2949 / 2956

Location

New Zealand

Related Subject Headings

  • 3214 Pharmacology and pharmaceutical sciences
  • 3209 Neurosciences
  • 3202 Clinical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences
  • 1103 Clinical Sciences